Results of a triple-blind study demonstrate effectiveness of zinc sulfate in preventing chemotherapy-induced mucositis or reducing its incidence and severity in patients with leukemia receiving chemotherapy.
1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing 
A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.
1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence 
A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.
Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.
Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.
The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.
Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.
A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.
Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.
What is the concern behind PARP inhibitors and leukemia?
Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.
US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.
Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.
Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.
[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.
Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.
Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.
Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.
The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy
For adults with relapsed or refractory AML who have an IDH2 genetic mutation
Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.
Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.
Standardized tool improved efficiency and thoroughness of patient assessment and documentation of neurotoxicity caused by high-dose cytarabine.
The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|